Top

Published in:

01-04-2017 | Rebuttal Letter

Response to “Do metastasis-free interval less or more than 24 months for recurrent metastatic breast cancer and primary surgery for de novo metastatic breast cancer matter for survival?”

Authors: Wendie D. den Brok, Caroline H. Speers, Lovedeep Gondara, Emily Baxter, Scott K. Tyldesley, Caroline A. Lohrisch

Published in: Breast Cancer Research and Treatment | Issue 2/2017

Excerpt

Dear Editor, …

den Brok WD, Speers CH, Gondara L, Baxter E, Tyldesley SK, Lohrisch CA (2016) Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed. Breast Cancer Res Treat. doi:10.1007/s10549-016-4080-9

Dawood S, Broglio K et al (2010) Survival differences among women with de novo stage IV and relapsed breast cancer. Ann Oncol 21:2169–2174CrossRefPubMedPubMedCentral

Marshall EM, Bertaut A, Desmoulins I et al (2016) Prognostic factors of survival among women with metastatic breast cancer and impact of primary or secondary nature of disease on survival: a French population-based study. Breast J. doi:10.1111/tbj.12717 PubMed

Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, van de Wouw AJ, Peters FP, van Riel JM, Peters NA, de Boer M, Peer PG, Tjan-Heijnen VC (2015) Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer? Br J Cancer 112(9):1445–1451CrossRefPubMedPubMedCentral

Soran A, Ozmen V, Ozbas S, Karanlik H, Muslumanoglu M, Igci A, Canturk Z, Utkan Z, Ozaslan C, Evrensel T, Uras C, Aksaz E, Soyder A, Ugurlu UM, Col C, Cabioglu N, Bozkurt B, Sezgin E, Johnson R, Lembersky BC (2016) A randomized controlled trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer: Turkish Study (Protocol MF07-01). 2016 ASCO Annual Meeting. Abstract 1005

Badwe R, Parmar V, Hawaldar R et al (2013) Surgical removal of primary tumor and axillary lymph nodes in women with metastatic breast cancer at first presentation: a randomized controlled trial. SABCS 2013. Abstract S2-02

King TA, Lyman J, Gonen M et al (2016) A prospective analysis of surgery and survival in stage IV breast cancer (TBCRC 013). 2016 ASCO Annual Meeting. Abstract 1006

Title: Response to “Do metastasis-free interval less or more than 24 months for recurrent metastatic breast cancer and primary surgery for de novo metastatic breast cancer matter for survival?”
Authors: Wendie D. den Brok
Caroline H. Speers
Lovedeep Gondara
Emily Baxter
Scott K. Tyldesley
Caroline A. Lohrisch
Publication date: 01-04-2017
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2017
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-017-4114-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2017

Determinants of volumetric breast density in Chilean premenopausal women

Oncoplastic surgery with omental flap reconstruction: a study of 200 cases

Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study

Impact of self-reported data on the acquisition of multi-generational family history and lifestyle factors among women seen in a high-risk breast screening program: a focus on modifiable risk factors and genetic referral

FGD5 amplification in breast cancer patients is associated with tumour proliferation and a poorer prognosis

Systematic development of an abbreviated protocol for screening breast magnetic resonance imaging

Keynote webinar | Spotlight on antibody–drug conjugates in cancer